BioCanada
Filter News
Found 36,219 articles
-
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
4/3/2024
AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
-
Alexion Canada Appoints Karen Heim as New General Manager
4/2/2024
Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.
-
Spectral Medical Chair to Retire From the Board of Directors
4/2/2024
Spectral Medical Inc. announced that Anthony Bihl III, Spectral’s Chairman, will be retiring from the Board at Spectral’s upcoming Shareholder Meeting in June 2024.
-
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
4/2/2024
Revive Therapeutics Ltd. is pleased to provide an update on the Company’s clinical study evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder conducted under an investigator-initiated IND at the University of Wisconsin-Madison, School of Medicine and Public Health and School of Pharmacy.
-
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
4/2/2024
Arch Biopartners Inc., announced that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury.
-
Genetesis Announces Formal Publication of Results from the MAGNETO Trial
4/2/2024
Genetesis, Inc., a leader in the field of magnetocardiography (MCG), today announced that official results from its MAGNETO trial were published in a special issue of the American Heart Journal Plus: Cardiology Research and Practice.
-
StageZero Life Sciences Announces Delay to Fourth Quarter and Year End 2023 Financial Results
4/2/2024
StageZero Life Sciences, Ltd. announced a delay in the filing of its audited consolidated financial statements for the year ended December 31, 2023, management's discussion and analysis for the same period and management certifications of annual filings beyond the deadline of April 2, 2024 prescribed by Canadian securities laws.
-
Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial
4/2/2024
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications
-
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
4/2/2024
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024
-
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
4/2/2024
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announces its year-end 2023 update on operations following the filing of its audited Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2023.
-
Microbix Announces Annual and Special Meeting Voting Results - April 01, 2024
4/1/2024
Microbix Biosystems Inc., a life sciences innovator and exporter, announces the voting results from the Annual and Special Meeting of Shareholders of the Company which was held on March 27, 2024.
-
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
4/1/2024
Antibe Therapeutics Inc. announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration that otenaproxesul has been placed on clinical hold, postponing the initiation of the planned Phase II trial.
-
BioSyent to Present at LD Micro New York Investor Conference
4/1/2024
BioSyent Inc. announces that Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person at the LD Micro Invitational XIV Conference in New York City on Tuesday, April 9th at 8:00am EDT.
-
MedMira Reports Second Quarter Results FY2024
4/1/2024
MedMira Inc., reported on its financial results for the quarter ended January 31, 2024.
-
FSD Pharma Announces Filing of Year-End 2023 Results
4/1/2024
FSD Pharma Inc. announced that the Company filed its audited annual financial results for the fourth quarter and full year ended December 31, 2023 and accompanying management's discussion and analysis on Thursday March 28, 2024 and today filed its Annual Report on 20-F for the year ended December 31, 2023.
-
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
4/1/2024
ProMIS Neurosciences Inc., a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy, announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update.
-
Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
4/1/2024
Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2023.
-
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
4/1/2024
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month.
-
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results
4/1/2024
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results (prepared in accordance with U.S. GAAP) and operational highlights for the fourth quarter ended December 31, 2023.
-
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
3/28/2024
IPA, InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with ImmunoPrecise Antibodies Ltd., an artificial intelligence-driven biotherapeutic research and technology company, are thrilled to announce a landmark collaboration.